Physician profile
Gary M Pepper
NPI 1881608545
$31,888.94
in general payments reported to CMS, 2019-2025
55 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,767 · 2020: $11K · 2021: $4,417 · 2022: $4,590 · 2023: $5,397 · 2024: $2,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,975 · Food and Beverage: $1,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,975.00 |
| Food and Beverage | $1,346.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $11,052.77 | 2019-2022 | |
| Abbvie INC. | $10,038.80 | 2019-2024 | |
| Novo Nordisk INC | $1,427.75 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $1,126.88 | 2019-2023 | |
| Tosoh Bioscience, INC. | $1,078.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $691.34 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $550.28 | 2019-2023 | Mounjaro, Jardiance, Lyumjev |
| Endo Pharmaceuticals INC. | $531.57 | 2019-2023 | Aveed |
| Bayer Healthcare Pharmaceuticals INC. | $489.58 | 2021-2023 | |
| Mannkind Corporation | $453.41 | 2019-2023 | Afrezza |
| Insulet Corporation | $401.69 | 2019-2023 | Omnipod |
| Amarin Pharma, INC. | $378.42 | 2019-2021 | |
| Amgen INC. | $293.24 | 2019-2023 | Repatha, Prolia, Evenity |
| Abbott Laboratories | $275.38 | 2019-2023 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $271.32 | 2020-2023 | Gvoke Hypopen |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Pepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.